Ser715
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser715  -  CTNNB1 (human)

Site Information
GYRQDDPsyRsFHsG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 25288326

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
brain cancer ( 1 ) , glioblastoma ( 1 ) , glioma ( 1 ) , lung cancer ( 2 ) , non-small cell lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 )
Relevant cell line - cell type - tissue:
NCI-H441 (pulmonary) ( 2 ) , U87MG (glial) ( 1 )

Upstream Regulation
Putative in vivo kinases:
PKCD (human) ( 1 )
Kinases, in vitro:
PKCD (human) ( 1 )

Downstream Regulation
Effects of modification on CTNNB1:
molecular association, regulation ( 1 ) , protein degradation ( 1 )
Induce interaction with:
TIF1G (human) ( 1 )

References 

1

Xue J, et al. (2015) Tumour suppressor TRIM33 targets nuclear β-catenin degradation. Nat Commun 6, 6156
25639486   Curated Info

2

Moritz A (2009) CST Curation Set: 7849; Year: 2009; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info